Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Fig. 1

SEMA6A is a prognostic indicator in BRAF-mut melanoma patients. A: SEMA6A Immunohistochemical assessment in BRAF-wt and BRAF-mut melanoma specimens of RECI1 cohort. Pearson’s Chi-square test revealed a significant association between SEMA6A expression and BRAF mutation (p < 0,0001). B: Representative sections from 2 BRAF-wt and 2 BRAF-mut melanoma patients, stained with anti-SEMA6A antibody. C: Progression-free Survival (PFS) and D: Overall Survival (OS) in patients with with high and low SEMA6A (BRAF-mut advanced melanoma). E: Relapse-free survival (RFS) in patients with high and low SEMA6A (BRAF-mut early melanoma) from the cohorts TCGA and DFCI

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us